- Home
- ANIP
as of 03-06-2026 3:55pm EST
$74.20
$1.41
-1.86%
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.7B | IPO Year: | 1999 |
| Target Price: | $107.33 | AVG Volume (30 days): | 324.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.32 | EPS Growth: | 419.23 |
| 52 Week Low/High: | $56.71 - $99.50 | Next Earning Date: | 05-11-2026 |
| Revenue: | $206,547,000 | Revenue Growth: | 2.47% |
| Revenue Growth (this year): | 19.88% | Revenue Growth (next year): | 15.77% |
| P/E Ratio: | 22.77 | Index: | N/A |
| Free Cash Flow: | 171.4M | FCF Growth: | +258.70% |
AI-Powered ANIP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 79.38%
79.38%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
CAREY STEPHEN P.
Sell
SVP & CFO
ANIP Mar 5, 2026
Avg Cost/Share
$75.49
Shares
7,312
Total Value
$552,031.04
Owned After
185,543
Gutwerg Ori
Sell
SVP, GENERICS
ANIP Mar 3, 2026
Avg Cost/Share
$76.50
Shares
2,060
Total Value
$157,590.00
Owned After
84,782
SEC Form 4
Walsh Patrick D
Sell
Director
ANIP Mar 3, 2026
Avg Cost/Share
$74.23
Shares
6,000
Total Value
$445,380.00
Owned After
52,405
SEC Form 4
Mutz Christopher
Sell
HEAD OF RARE DISEASE
ANIP Mar 2, 2026
Avg Cost/Share
$74.00
Shares
417
Total Value
$30,858.00
Owned After
103,508
SEC Form 4
Mutz Christopher
Sell
HEAD OF RARE DISEASE
ANIP Feb 20, 2026
Avg Cost/Share
$78.02
Shares
5,323
Total Value
$415,300.46
Owned After
103,508
SEC Form 4
Davis Krista
Sell
SVP, CHIEF HR OFFICER
ANIP Feb 20, 2026
Avg Cost/Share
$77.99
Shares
1,730
Total Value
$134,922.70
Owned After
49,263
SEC Form 4
Davis Krista
Sell
SVP, CHIEF HR OFFICER
ANIP Feb 19, 2026
Avg Cost/Share
$77.53
Shares
2,084
Total Value
$161,572.52
Owned After
49,263
SEC Form 4
Cook Meredith
Sell
SR. VP, GENERAL COUNSEL & SEC.
ANIP Feb 13, 2026
Avg Cost/Share
$76.80
Shares
500
Total Value
$38,400.00
Owned After
69,329
SEC Form 4
Mutz Christopher
Sell
HEAD OF RARE DISEASE
ANIP Feb 12, 2026
Avg Cost/Share
$76.55
Shares
7,032
Total Value
$538,299.60
Owned After
103,508
SEC Form 4
Cook Meredith
Sell
SR. VP, GENERAL COUNSEL & SEC.
ANIP Jan 13, 2026
Avg Cost/Share
$84.33
Shares
500
Total Value
$42,165.00
Owned After
69,329
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| CAREY STEPHEN P. | ANIP | SVP & CFO | Mar 5, 2026 | Sell | $75.49 | 7,312 | $552,031.04 | 185,543 | |
| Gutwerg Ori | ANIP | SVP, GENERICS | Mar 3, 2026 | Sell | $76.50 | 2,060 | $157,590.00 | 84,782 | |
| Walsh Patrick D | ANIP | Director | Mar 3, 2026 | Sell | $74.23 | 6,000 | $445,380.00 | 52,405 | |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | Mar 2, 2026 | Sell | $74.00 | 417 | $30,858.00 | 103,508 | |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | Feb 20, 2026 | Sell | $78.02 | 5,323 | $415,300.46 | 103,508 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Feb 20, 2026 | Sell | $77.99 | 1,730 | $134,922.70 | 49,263 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Feb 19, 2026 | Sell | $77.53 | 2,084 | $161,572.52 | 49,263 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Feb 13, 2026 | Sell | $76.80 | 500 | $38,400.00 | 69,329 | |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | Feb 12, 2026 | Sell | $76.55 | 7,032 | $538,299.60 | 103,508 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jan 13, 2026 | Sell | $84.33 | 500 | $42,165.00 | 69,329 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 27, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 27, 2026 · 100% conf.
AI Prediction BUY
1D
+1.48%
$74.71
Act: +2.17%
5D
+4.42%
$76.88
20D
+3.55%
$76.23
Price: $73.62 Prob +5D: 100% AUC: 1.000
0001023024-26-000013
ani-202602270001023024FALSE00010230242026-02-272026-02-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): February 27, 2026
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3181258-2301143 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
210 Main Street West Baudette, Minnesota 56623 (Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (218) 634-3500 Not Applicable (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockANIPNasdaq Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition
On February 27, 2026, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*
Item 9.01Exhibits
(d)Exhibits
Exhibit No.Description 99.1Press Release of the Company, dated February 27, 2026
104Cover Page Interactive Data File (embedded with the Inline XBRL document)
*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 27, 2026
ANI PHARMACEUTICALS, INC.
By:/s/ Stephen P. Carey Name:Stephen P. Carey Title:Senior Vice President Finance and Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
AI Prediction BUY
1D
+1.48%
$74.71
Act: +2.17%
5D
+4.42%
$76.88
20D
+3.55%
$76.23
Price: $73.62 Prob +5D: 100% AUC: 1.000
0001023024-26-000005
ani-202601120001023024FALSE00010230242026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3181258-2301143 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
210 Main Street West Baudette, Minnesota 56623 (Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (218) 634-3500 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockANIPNasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition
On January 12, 2026, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, as well as preliminary 2026 financial guidance. A copy of the press release is furnished herewith as Exhibit 99.1.*
The selected financial results are based on preliminary unaudited information and management estimates, are not a comprehensive statement of the Company’s financial results for either the fourth quarter or fiscal year ended December 31, 2025 and are subject to change. Such changes may be material. Our independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or provide any other form of assurance with respect to, these preliminary results.
In addition, on January 13, 2026, Nikhil Lalwani, President & CEO of the Company, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. A copy of the investor presentation is attached as Exhibit 99.2 hereto and incorporated herein by reference.*
Item 7.01 Regulation FD Disclosure
The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
Item 9.01Exhibits
(d)Exhibits
Exhibit No.Description 99.1Press Release of the Company, dated January 12, 2026
99.2Investor Presentation, dated January 2026
104Cover Page Interactive Data File (embedded with the Inline XBRL document)
*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 12, 2026ANI PHARMACEUTICALS, INC.
By:/s/ Stephen P. Carey Name:Stephen P. Carey Title:Senior Vice President Finance and Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 10, 2025
0001023024-25-000110
ani-202511100001023024FALSE00010230242025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 10, 2025
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3181258-2301143 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
210 Main Street West Baudette, Minnesota 56623 (Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (218) 634-3500 Not Applicable (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockANIPNasdaq Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition
On November 10, 2025, ANI Pharmaceuticals, Inc. (the “Company”) published an updated investor presentation to the investor relations section of its website. The Company may use the updated presentation in various meetings with investors, analysts, and others from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*
Item 7.01 Regulation FD Disclosure
The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
Item 9.01Exhibits
(d)Exhibits
Exhibit No.Description 99.1Investor Presentation, dated November 2025
104Cover Page Interactive Data File (embedded with the Inline XBRL document)
*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 10, 2025ANI PHARMACEUTICALS, INC.
By:/s/ Stephen P. Carey Name:Stephen P. Carey Title:Senior Vice President Finance and Chief Financial Officer
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
Compare ANIP vs Leading Stocks
See how ANIP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.